{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:24:59Z","timestamp":1794367499882,"version":"4.9.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["2019CXJQ03"],"award-info":[{"award-number":["2019CXJQ03"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700195"],"award-info":[{"award-number":["81700195"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470353"],"award-info":[{"award-number":["81470353"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870155"],"award-info":[{"award-number":["81870155"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-Young2023-0175"],"award-info":[{"award-number":["Y-Young2023-0175"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011790","name":"Xiangya Hospital, Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012543","name":"Shanghai Science and Technology Development Foundation","doi-asserted-by":"publisher","award":["19MC1911000"],"award-info":[{"award-number":["19MC1911000"]}],"id":[{"id":"10.13039\/100012543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2023.e23921","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T21:49:15Z","timestamp":1703627355000},"page":"e23921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-6512","authenticated-orcid":false,"given":"Ji-Wei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renfang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.heliyon.2023.e23921_bib1","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1002\/cam4.3037","article-title":"Improving survival of 3760 patients with lymphoma: experience of an academic center over two decades","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.heliyon.2023.e23921_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fonc.2018.00211","article-title":"Epstein-Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: an update","volume":"8","author":"Smatti","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2023.e23921_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein-Barr virus and cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu. Rev. Pathol."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e23921_bib4","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajh.26579","article-title":"EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management","volume":"97","author":"Malpica","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.heliyon.2023.e23921_bib5","article-title":"Characterization of artificial pneumothorax-unrelated pyothorax-associated lymphoma","volume":"2021","author":"Chen","year":"2021","journal-title":"J. Oncol."},{"issue":"15","key":"10.1016\/j.heliyon.2023.e23921_bib6","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23921_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201546","article-title":"Genetic heterogeneity and mutational signature in Chinese Epstein-Barr virus-positive diffuse large B-cell lymphoma","volume":"13","author":"Liu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2023.e23921_bib8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3389\/fonc.2019.00683","article-title":"Comprehensive genomic profiling of EBV-positive diffuse large B-cell lymphoma and the expression and clinicopathological correlations of some related genes","volume":"9","author":"Zhou","year":"2019","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23921_bib9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-021-00493-5","article-title":"Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing","volume":"11","author":"Gebauer","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23921_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12935-021-01793-3","article-title":"Signaling pathways of EBV-induced oncogenesis","volume":"21","author":"Luo","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"42","key":"10.1016\/j.heliyon.2023.e23921_bib11","doi-asserted-by":"crossref","first-page":"26318","DOI":"10.1073\/pnas.2007946117","article-title":"Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A","volume":"117","author":"Fish","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23921_bib12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/cas.12389","article-title":"Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways","volume":"105","author":"Kato","year":"2014","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e23921_bib13","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/cas.12812","article-title":"Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma","volume":"106","author":"Okamoto","year":"2015","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23921_bib14","doi-asserted-by":"crossref","first-page":"e769","DOI":"10.1097\/CAD.0000000000001187","article-title":"Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report","volume":"33","author":"Yu","year":"2022","journal-title":"Anti Cancer Drugs"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23921_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00000478-200301000-00003","article-title":"Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients","volume":"27","author":"Oyama","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23921_bib16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2013-03-489708","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly","volume":"122","author":"Ok","year":"2013","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.heliyon.2023.e23921_bib17","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23921_bib18","article-title":"Epstein-Barr virus and the pathogenesis of diffuse large B-cell lymphoma","volume":"13","author":"Ross","year":"2023","journal-title":"Life (Basel)"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e23921_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15072133","article-title":"EBV and lymphomagenesis","volume":"15","author":"Sausen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23921_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13000-018-0693-0","article-title":"Clinicopathological features and EBV infection status of lymphoma in children and adolescents in South China: a retrospective study of 662 cases","volume":"13","author":"Qin","year":"2018","journal-title":"Diagn. Pathol."},{"issue":"17","key":"10.1016\/j.heliyon.2023.e23921_bib21","first-page":"8947","article-title":"Clinical features and survival impact of EBV-positive diffuse large B-Cell lymphoma with different age cutoffs","volume":"24","author":"Nan","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23921_bib22","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/ajh.22078","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru","volume":"86","author":"Beltran","year":"2011","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e23921_bib23","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/modpathol.2015.94","article-title":"Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy","volume":"28","author":"Liu","year":"2015","journal-title":"Mod. Pathol."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e23921_bib24","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1158\/1078-0432.CCR-13-3157","article-title":"Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries","volume":"20","author":"Ok","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2023.e23921_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.virol.2016.10.015","article-title":"Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton's tyrosine kinase and STAT3","volume":"500","author":"Incrocci","year":"2017","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23921_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1683346","article-title":"Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture\/presentation and hijacked T-cell suppression","volume":"9","author":"Jiang","year":"2020","journal-title":"OncoImmunology"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23921_bib27","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41375-022-01804-w","article-title":"Molecular profiling of EBV associated diffuse large B-cell lymphoma","volume":"37","author":"Frontzek","year":"2023","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e23921_bib28","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/cncr.34698","article-title":"TET2 and LILRB1 mutations are frequent in Epstein-Barr virus-positive diffuse large B-cell lymphoma especially in elderly patients","volume":"129","author":"Cho","year":"2023","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23921_bib29","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cell.2011.12.031","article-title":"Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model","volume":"148","author":"Zhang","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23921_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/PAI.0000000000000583","article-title":"Evaluation of PD1\/PDL1 expression and their clinicopathologic association in EBV-associated lymphoproliferative disorders in nonimmunosuppressed patients","volume":"27","author":"Guo","year":"2019","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23921_bib31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/gcc.22249","article-title":"Integrated copy number and gene expression profiling analysis of Epstein-Barr virus-positive diffuse large B-cell lymphoma","volume":"54","author":"Yoon","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.heliyon.2023.e23921_bib32","article-title":"Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age","volume":"5","author":"Lu","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23921_bib33","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s12916-022-02683-9","article-title":"Clinicopathologic features and abnormal signaling pathways in plasmablastic lymphoma: a multicenter study in China","volume":"20","author":"Shi","year":"2022","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23921_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5045\/br.2020.55.1.49","article-title":"HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases","volume":"55","author":"Li","year":"2020","journal-title":"Blood Res."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e23921_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2015-02-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae","year":"2015","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.heliyon.2023.e23921_bib36","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/bloodadvances.2021004515","article-title":"Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified","volume":"5","author":"Bourbon","year":"2021","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e23921_bib37","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.humpath.2007.05.020","article-title":"Epstein-Barr virus-associated lymphoproliferative disorders","volume":"38","author":"Rezk","year":"2007","journal-title":"Hum. Pathol."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23921_bib38","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/modpathol.2011.62","article-title":"Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population","volume":"24","author":"Hofscheier","year":"2011","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e23921_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133973","article-title":"Epstein-Barr virus-positive diffuse large B-cell lymphoma in the elderly: a matched case-control analysis","volume":"10","author":"Song","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23921_bib40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/bjh.16342","article-title":"Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma","volume":"189","author":"Witte","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23921_bib41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00428-020-02901-w","article-title":"Clinicopathological analysis of neoplastic PD-L1-positive EBV(+) diffuse large B cell lymphoma, not otherwise specified, in a Japanese cohort","volume":"478","author":"Takahara","year":"2021","journal-title":"Virchows Arch."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23921_bib42","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00277-020-04005-6","volume":"99","author":"Yoon","year":"2020","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23921_bib43","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23921_bib44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/path.5108","article-title":"Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma","volume":"246","author":"Liu","year":"2018","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23921_bib45","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/leu.2017.299","article-title":"HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma","volume":"32","author":"Jia","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23921_bib46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2015.03.016","article-title":"Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma","volume":"364","author":"Shin","year":"2015","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23921_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2018.01.004","article-title":"Safety and preliminary efficacy of Vorinostat with R-EPOCH in high-risk HIV-associated non-hodgkin's lymphoma (AMC-075)","volume":"18","author":"Ramos","year":"2018","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23921_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1995166","article-title":"Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma","volume":"10","author":"Li","year":"2021","journal-title":"OncoImmunology"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23921_bib49","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/his.13765","article-title":"Integrative analysis of PD-L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B-cell lymphoma","volume":"74","author":"Sun","year":"2019","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e23921_bib50","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.pathol.2018.08.011","article-title":"EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression","volume":"50","author":"Xue","year":"2018","journal-title":"Pathology"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23921_bib51","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10238-021-00754-4","article-title":"Programmed cell death-ligand 1 (PD-L1)(+) tumour cells and low-reacting programmed cell death 1 (PD1)(+) tumour-infiltrating lymphocytes predict poor prognosis in Epstein-Barr virus(+) diffuse large B-cell lymphoma","volume":"22","author":"Kimura","year":"2022","journal-title":"Clin. Exp. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23921_bib52","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1182\/bloodadvances.2022008344","article-title":"Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma","volume":"7","author":"Younes","year":"2023","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23921_bib53","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/bjh.16494","article-title":"Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy","volume":"189","author":"Smith","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23921_bib54","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7555\/JBR.28.20140066","article-title":"T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo","volume":"28","author":"Tang","year":"2014","journal-title":"J. Biomed. Res."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23921_bib55","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23921_bib56","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3892\/ijo.2017.3923","article-title":"A p110delta-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-kappaB","volume":"50","author":"Park","year":"2017","journal-title":"Int. J. Oncol."},{"issue":"16","key":"10.1016\/j.heliyon.2023.e23921_bib57","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2015-03-632430","article-title":"Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL","volume":"126","author":"Offner","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e23921_bib58","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/ajt.15216","article-title":"Dual blockade of the PI3K\/Akt\/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival","volume":"19","author":"Sang","year":"2019","journal-title":"Am. J. Transplant."},{"issue":"21","key":"10.1016\/j.heliyon.2023.e23921_bib59","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1074\/jbc.RA120.012645","article-title":"The mTOR inhibitor manassantin B reveals a crucial role of mTORC2 signaling in Epstein-Barr virus reactivation","volume":"295","author":"Wang","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/j.heliyon.2023.e23921_bib60","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.7150\/thno.42494","article-title":"A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.heliyon.2023.e23921_bib61","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3389\/fimmu.2018.00932","article-title":"Immunization with Fc-based recombinant epstein-barr virus gp350 elicits potent neutralizing humoral immune response in a BALB\/c mice model","volume":"9","author":"Zhao","year":"2018","journal-title":"Front. Immunol."},{"issue":"34","key":"10.1016\/j.heliyon.2023.e23921_bib62","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","article-title":"Rabbits immunized with Epstein-Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350","volume":"34","author":"Cui","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23921_bib63","doi-asserted-by":"crossref","first-page":"B194","DOI":"10.1016\/j.vaccine.2012.09.041","article-title":"The need and challenges for development of an Epstein-Barr virus vaccine","volume":"31","author":"Cohen","year":"2013","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23921_bib64","doi-asserted-by":"crossref","first-page":"e1033","DOI":"10.1097\/MPH.0000000000002403","article-title":"Epstein-Barr virus in childhood and adolescent classic Hodgkin lymphoma in a French cohort of 301 patients","volume":"44","author":"Pereira","year":"2022","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2023.e23921_bib65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-9378-5-13","article-title":"Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study","volume":"5","author":"Asito","year":"2010","journal-title":"Infect. Agents Cancer"},{"issue":"17","key":"10.1016\/j.heliyon.2023.e23921_bib66","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-06-2823","article-title":"Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients","volume":"13","author":"Oyama","year":"2007","journal-title":"Clin. Cancer Res."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023111297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023111297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:28:53Z","timestamp":1790656133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023111297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844023111297"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23921","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e23921"}}